Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback